Primary Effusion Lymphoma cell death induced by Bortezomib and AG 490 activates dendritic cells through CD91

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Cirone, Mara ^a   Di Renzo, Livia ^a   Lotti, Lavinia Vittoria ^a   Conte, Valeria ^a   Trivedi, Pankaj ^a   Santarelli, Roberta ^a   Gonnella, Roberta ^a   Frati, Luigi ^a   Faggioni, Alberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CALRETICULIN; CASPASE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NEUTRALIZING ANTIBODY; ALPHA CYANO (3,4 DIHYDROXY) N BENZYLCINNAMIDE; ALPHA-CYANO-(3,4-DIHYDROXY)-N-BENZYLCINNAMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE; TYRPHOSTIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL KINETICS; CELL MATURATION; CELL STIMULATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATIONAL STUDY; DENDRITIC CELL; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; LYMPHOMA CELL; PHAGOCYTOSIS; PRIMARY EFFUSION LYMPHOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; CELL LINE; DRUG EFFECT; IMMUNOLOGY; KINETICS; METABOLISM; PROTEIN TRANSPORT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CALRETICULIN; CELL LINE; DENDRITIC CELLS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; KINETICS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; LYMPHOMA, PRIMARY EFFUSION; PHAGOCYTOSIS; PROTEIN TRANSPORT; PYRAZINES; TYRPHOSTINS;

EID: 84857879286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031732     Document Type: Article

References (35)

1. Aoki Y, Tosato G, (2003) Pathogenesis and manifestations of human herpesvirus-8-associated disorders. Semin Hematol 40: 143-153.
2. Nador RG, Cesarman E, Chadburn A, Dawson DB, Sald J, et al. (1996) Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 88: 645-656.
3. Matta H, Chaudhary PM, (2005) The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther 4: 77-82.
4. Chari A, Mazumder A, Jagannath S, (2010) Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics 4: 273-287.
5. Aoki Y, Feldman GM, Tosato G, (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101: 1535-1542.
6. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, et al. (2010) Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 1805: 53-71.
7. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, et al. (2009) Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 14: 364-375.
8. Haynes NM, Van der Most RG, Lake RA, Smyth MJ, (2008) Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol 20: 545-557.
9. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, et al. (2008) Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15: 3-12.
10. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L, (2008) Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 68: 4026-4030.
11. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, et al. (2010) Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 16: 3100-3104.
12. Spisek R, Dhodapkar MV, (2007) Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle 6: 1962-1965.
13. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, et al. (2011) Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30: 1147-1158.
14. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, et al. (2007) Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109: 4839-4845.
15. Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, et al. (2010) Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 70: 9062-9072.
16. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, et al. (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202: 1691-1701.
17. Petersen TR, Dickgreber N, Hermans IF, (2010) Tumor antigen presentation by dendritic cells. Crit Rev Immunol 30: 345-386.
18. Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L, (2011) The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol 23: 146-152.
19. Facciponte JG, MacDonald IJ, Wang XY, Kim H, Manjili MH, et al. (2005) Heat shock proteins and scavenger receptors: role in adaptive immune responses. Immunol Invest 34: 325-342.
20. Basu S, Binder RJ, Ramalingam T, Srivastava PK, (2001) CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14: 303-313.
21. Stebbing J, Gazzard B, Portsmouth S, Gotch F, Kim L, et al. (2003) Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor. Blood 102: 1806-1814.
22. Demaria S, Santori FR, Ng B, Liebes L, Formenti SC, et al. (2005) Select forms of tumor cell apoptosis induce dendritic cell maturation. J Leukoc Biol 77: 361-368.
23. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, et al. (2008) Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 20: 504-511.
24. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61.
25. Chaput N, De Botton S, Obeid M, Apetoh L, Ghiringhelli F, et al. (2007) Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med 85: 1069-1076.
26. Becker T, Hartl FU, Wieland F, (2002) CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol 158: 1277-1285.
27. Gardai SJ, Bratton DL, Ogden CA, Henson PM, (2006) Recognition ligands on apoptotic cells: a perspective. J Leukoc Biol 79: 896-903.
28. Binder RJ, Srivastava PK, (2004) Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci U S A 101: 6128-6133.
29. Stebbing J, Gazzard B, Kim L, Portsmouth S, Wildfire A, et al. (2003) The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressors. Blood 101: 4000-4004.
30. Kebba A, Stebbing J, Rowland S, Ingram R, Agaba J, et al. (2005) Expression of the common heat-shock protein receptor CD91 is increased on monocytes of exposed yet HIV-1-seronegative subjects. J Leukoc Biol 78: 37-42.
31. Nencioni A, Garuti A, Schwarzenberg K, Cirmena G, Dal Bello G, et al. (2006) Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol 36: 681-689.
32. Cirone M, Di Renzo L, Trivedi P, Lucania G, Borgia G, et al. (2010) Dendritic cell differentiation blocked by primary effusion lymphoma-released factors is partially restored by inhibition of P38 MAPK. Int J Immunopathol Pharmacol 23: 1079-1086.
33. Cirone M, Lucania G, Aleandri S, Borgia G, Trivedi P, et al. (2008) Suppression of dendritic cell differentiation through cytokines released by Primary Effusion Lymphoma cells. Immunol Lett 120: 37-41.
34. Bharadwaj U, Li M, Zhang R, Chen C, Yao Q, (2007) Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 67: 5479-5488.
35. Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, et al. (2009) Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol Cancer Ther 8: 2211-2220.